Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) shares are trading higher by 15.8% to $1.17 during Friday’s session after the company and Galapagos entered a clinical collaboration to license ...

ADAPTIMMUNE THERAPEUTICS ($ADAP) posted quarterly earnings results on Tuesday, May 13th. The company reported earnings of -$0.18 per share, missing estimates of -$0. ...

The most recent trading session ended with Adaptimmune Therapeutics PLC (ADAP) standing at $1.20, reflecting a -1.24% shift from the previouse trading day's closing. This move was narrower than the ...

Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and ...

In a single day, the talk on the Street has zeroed in on one stock, oncology-focused cell therapy company Adaptimmune Therapeutics (ADAP). Following its presentation of promising data at the 38th ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. is fair to ...

Seeing as Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADP) has experienced bearish sentiment from the aggregate hedge fund industry, logic holds that there lies a certain “tier” of money managers that ...